Related Experiment Video
Updated: Dec 31, 2025

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives
Bala Waziri1,2, Raquel Duarte1, Saraladevi Naicker1
1Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Insights
Chronic kidney disease-mineral and bone disorder (CKD-MBD) affects many patients despite guidelines. Recent advances, including fibroblast growth factor 23 (FGF23) and updated KDIGO recommendations, are improving CKD-MBD management.
Area of Science:
- Nephrology
- Endocrinology
- Biochemistry
Background:
- Chronic kidney disease-mineral and bone disorder (CKD-MBD) remains prevalent despite existing guidelines.
- Adverse clinical outcomes persist in CKD patients due to CKD-MBD.
- Continuous research aims to enhance the understanding and management of CKD-MBD.
Purpose of the Study:
- To provide an overview of the evolving trends in CKD-MBD.
- To connect historical and contemporary concepts of CKD-MBD.
- To highlight recent advancements in CKD-MBD research and clinical practice.
Main Methods:
- Review of scientific literature and clinical trial data.
- Analysis of the impact of fibroblast growth factor 23 (FGF23) on CKD-MBD pathogenesis.
- Examination of shifts in diagnostic and therapeutic approaches for CKD-MBD.
Main Results:
- Discovery of fibroblast growth factor 23 (FGF23)'s role, updating the trade-off hypothesis.
- Transition from single biomarker measurements to serial monitoring of calcium, phosphate, and parathyroid hormone (PTH).
- Emergence of new clinical trials leading to updated Kidney Disease-Improving Global Outcomes (KDIGO) guidelines in 2017.
Conclusions:
- CKD-MBD management has significantly evolved.
- Understanding of CKD-MBD pathogenesis has advanced with new discoveries like FGF23.
- Updated guidelines and monitoring strategies offer improved clinical care for CKD-MBD patients.
Abstract:
Despite the availability of global and regional guidelines to curtail the adverse clinical outcomes associated with chronic kidney disease-mineral and bone disorder (CKD-MBD), most CKD patients are still affected by the consequences of abnormalities of CKD-MBD. This important clinical complication of CKD continues to be studied, in order to improve the understanding and management of CKD-MBD. Some notable discoveries include the role of fibroblast growth factor 23 (FGF23) in the pathogenesis of CKD-MBD, leading to a shift from the previous well-established classic trade-off hypothesis to the updated trade-off hypothesis. More recently, there has been a shift from the treatment of CKD-MBD based on a single level of biomarkers to serial measurements of calcium, phosphate and parathyroid hormone (PTH). Furthermore, some clinical trials have emerged after the 2009 Kidney Disease-Improving Global Outcomes (KDIGO) Guidelines, leading to the 2017 KDIGO updated recommendations. Hence, this review gives an overview of the rapidly evolving trends in CKD-MBD, linking the past and current concepts of CKD-MBD.
More Related Videos
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care

